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Abstract 
Background: A major goal in the search for new anti-malarial compounds is to identify new mechanisms of action 
or new molecular targets. While cell-based, growth inhibition-based screening have enjoyed tremendous success, an 
alternative approach is to specifically assay a given pathway or essential cellular process.
Methods: Here, this work describes the development of a plate-based, in vitro luciferase assay to probe for inhibitors 
specific to protein synthesis in Plasmodium falciparum through the use of an in vitro translation system derived from 
the parasite.
Results: Using the Medicines for Malaria Venture’s Malaria Box as a pilot, 400 bioactive compounds with minimal 
human cytotoxicity profiles were screened, identifying eight compounds that displayed greater potency against the P. 
falciparum translation machinery relative to a mammalian translation system. Dose–response curves were determined 
in both translation systems to further characterize the top hit compound (MMV008270).
Conclusions: This assay will be useful not only in future anti-malarial screening efforts but also in the investigation of 
P. falciparum protein synthesis and essential processes in P. falciparum biology.
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Background
Identifying new anti-malarials with novel mechanisms 
of action is a key goal in the fight to eradicate malaria 
worldwide [1]. A common and very successful strategy 
relies on screening in  vitro cultures of Plasmodium fal-
ciparum against large compound collections and assay-
ing for growth inhibition in a ‘top-down’ approach to 
drug discovery. Using this type of approach can result 
in the subsequent identification of drug targets by selec-
tion of resistant strains and whole genome sequencing of 
these resistant strains to identify mutations (i.e., single 
nucleotide polymorphisms, copy number variants, inser-
tions/deletions) that confer resistance [2–4]. However, 
one challenge with this approach is the high likelihood 
of encountering new compounds associated with targets 
that have previously been exploited as opposed to identi-
fying new mechanisms of action. This has certainly been 
the case in recent instances, in which multiple groups 
have identified diverse chemical compounds that all have 
the same molecular determinants of resistance, such 
as PfATP4, and quite possibly the same mechanism of 
action [2, 5, 6] .
The complementary strategy is to narrow the search 
criteria by assaying for activity against a specific bio-
logical function or pathway. For example, this approach 
was used to identify a specific inhibitor of PfIspD, an 
enzyme essential for isoprenoid synthesis, by counter 
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screening with growth media supplemented with iso-
pentenyl pyrophosphate (IPP), thus narrowing hits to 
only those active against apicoplast targets (such as iso-
prenoid enzymes) [4]. Facilitating these efforts, the freely 
available Medicines for Malaria Venture (MMV) Malaria 
Box has been a welcome resource, providing biologically 
active compounds with unknown targets and mecha-
nisms of action [7]. The library contains 400 chemically 
diverse compounds that are commercially available and 
pre-screened for activity in the blood stages of P. falcipa-
rum with minimal human cytotoxicity.
Among the possible pathways that can be functionally 
assayed, protein synthesis represents an attractive target, 
given its absolutely essential nature. Indeed, despite the 
fact that P. falciparum is a eukaryotic organism, there are 
ample differences between the P. falciparum and mam-
malian ribosomes that could be plausibly exploited [8, 9]. 
In fact, precedence for this type of inhibition of protein 
synthesis was exemplified in the discovery of the sordarin 
class of natural products which selectively inhibits fungal 
protein synthesis by inhibiting the yeast eukaryotic elon-
gation factor 2 [10]. In a similar manner, a potent new 
compound, DDD107498, was reported to specifically 
inhibit P. falciparum protein synthesis by blocking activ-
ity of the P. falciparum translation eukaryotic elongation 
factor 2 [11]. Here, this study reports the use of a P. falci-
parum in vitro translation assay, amenable to plate-based 
screening, to identify inhibitors of P. falciparum transla-
tion present in the Malaria Box.
Methods
Plasmodium falciparum culturing
W2 strains were maintained in HYPERFlasks (Corning, 
Corning, NY, USA) in 500 mL RPMIc [RPMI 1640 media 
supplemented with 0.25  % Albumax II (GIBCO, Grand 
Island, NY, USA), 2  g/L sodium bicarbonate, 25  mM 
HEPES (pH 7.4), 0.1 mM hypoxanthine, and 50 ug/L gen-
tamycin] in a 37  °C, 5 % O2, 5 % CO2 incubator in 2 % 
haematocrit (HC). Cells were synchronized with 5  % 
sorbitol treatment for two generations to achieve high 
synchronicity.
Harvesting cell pellets
One liter parasite cultures grown in two 500  mL 
HYPER flasks were harvested in the late trophozoite 
stage at approximately 15  % parasitaemia by centrifu-
gation for 5  min at 1500×g at room temperature and 
0.06 % final saponin in Buffer A (20 mM HEPES pH 8.0, 
2 mM Mg(OAc)2, 120 mM KOAc). Saponin lysed pellets 
were centrifuged at 4 °C 10,000×g for 10 min and washed 
once with ice-cold Buffer A. The pellet was resuspended 
in 2  mL of Buffer B2 [20  mM HEPES pH 8.0, 100  mM 
KOAc, 0.75 mM Mg(OAC)2, 2 mM DTT, 20 % glycerol, 
1× protease inhibitor cocktail (Roche)], flash frozen, and 
stored in −80  °C freezer until the sample was ready to 
homogenize.
Homogenization of cell pellets
Frozen pellets were thawed on ice and added to a 3-mL 
luer lock syringe, locked onto a pre-chilled cell homog-
enizer (Isobiotec, Germany) on ice and passed between 
two syringes 20 times. Lysate was centrifuged at 4  °C 
16,000×g for 10  min and the supernatant was stored at 
−80 °C.
In vitro translation assay
Plasmodium in  vitro translation reactions were carried 
out v-bottom 96-well PCR plates (USA Scientific, Ocala, 
FL, USA) and sealed with adhesive aluminum foil plate 
seals (Beckman Coulter, Indianapolis, IN, USA) with 
the following components in 20  μL: 16  μL lysate, 1  μg 
T7 transcribed firefly luciferase mRNA, 10  µM amino 
acid mixture, 20  mM HEPES/KOH pH 8.0, 75  mM 
KOAc, 2  mM  Mg(OAc)2, 2  mM DTT, 0.5  mM ATP, 
0.1 mM GTP, 20 mM creatine phosphate, 0.2 μg/μl cre-
atine kinase for 0.5–1.5 h at 37 °C. All liquid dispensing 
was performed using Rainin E4 12-channel electronic 
pipettes (Rainin Instruments, Oakland, CA, USA). After 
incubation, the reactions were quenched with a final con-
centration of 5  µM cycloheximide. Samples were trans-
ferred to a 96-well LUMITRAC 200 white immunology 
plate (Greiner Bio-One, Monroe, NC, USA). Reactions 
were assayed using the Promega GloMax-Multi + micro-
plate reader with a three-second delay and ten-second 
integration after addition of 100 μL luciferin reagent 
(20 mM Tricine, 2.67 mM MgSO4×7H2O, 0.1 mM EDTA, 
33.3 mM DTT, 530 μM ATP, 270 μM Acetyl CoEnzyme 
A, 1  mM D-Luciferin, 265  μM Magnesium Carbonate 
Hydroxide, pH 8.15).
Rabbit reticulocyte (Retic Lysate IVT Kit, Thermo 
Fisher Scientific, Waltham, MA, USA) in vitro translation 
assays were carried out with the following components 
in 20 μL: 0.5 μL 20× translation mix minus methionine, 
0.5 μL 20× translation mix minus leucine, 1 μg T7 tran-
scribed firefly luciferase mRNA, and 18  μL reticulo-
cyte lysate for 5–20  min at 37  °C. After incubation, the 
reactions were quenched with 5  µM cycloheximide and 
assayed in the same manner as the Plasmodium lysates.
Drug screening
The open-access Malaria Box was obtained from MMV. 
Initial screens were performed at 1  μM final drug con-
centration in v-bottom 96-well PCR plates (USA 
Scientific, Ocala, FL, USA) and sealed with adhesive alu-
minum foil plate seals (Beckman Coulter, Indianapolis, 
IN, USA). The 20  μL reaction contained the following 
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components in 20 μL: 14 μL lysate, 1 μg T7 transcribed 
firefly luciferase mRNA, 10  µM amino acid mixture, 
20  mM HEPES/KOH pH 8.0, 75  mM KOAc, 2  mM 
Mg(OAc)2, 2  mM DTT, 0.5  mM ATP, 0.1  mM GTP, 
20  mM creatine phosphate, 0.2  μg/μl creatine kinase. 
After the 1.5  h incubation, samples were immediately 
quenched using 2μL of 50 μM cycloheximide stop solu-
tion and then transferred to the Lumitrac assay plate 
using 12-channel electronic pipettes and assayed in the 
same manner described in the above in vitro translation 
assay. IC50 values were determined with a constant 2.5 % 
DMSO, using a 12-point 1:3 titration starting at 250 μM. 
Data were normalized to background and DMSO-only 
controls.
Results
Development of a high‑throughput, malaria‑specific, 
in vitro translation assay
Building upon the work of Ferreras et  al., an in  vitro 
translation assay was further developed and optimized 
from P. falciparum cultures with the addition of exog-
enous firefly luciferase reporter mRNAs to allow for 
high-throughput plate-based luciferase assay screen-
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Fig. 1 Development of a luciferase based in vitro translation assay in Plasmodium falciparum. a Workflow for preparing lysate for in vitro transla-
tion assay. b Plasmid construct to generate mRNA transcripts containing a P. falciparum specific 5′ and 3′ UTR with a firefly luciferase open reading 
frame. Maxipreps of the plasmid were digested with PvuII and BamHI to create the templates for T7 transcription to make a final mRNA with the P. 
falciparum UTRs and firefly luciferase. c Lysates were incubated in the presence of a 10 × magnesium-containing translation buffer and luciferase 
mRNAs for a time course of 30 min to 120 min followed by the addition of luciferin reagent to assay for luciferase activity. d Lysates were incubated 
with DMSO control only or with 5 μM cycloheximide before or after the 120-min incubation followed by assaying for luciferase output
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HYPERFlasks (Corning) using synchronized, high-den-
sity, late trophozoite cultures, and utilized a saponin 
lysis method to release the parasites from the red blood 
cells (see “Methods” section). To maintain consistency 
of lysis conditions, a cell homogenizer (Isobiotec, Ger-
many) was utilized, which gently and uniformly breaks 
open cells by passing the lysate though a precise 4-µM 
ball-bearing clearance, a technique that has found wide-
spread use in sub-cellular fractionation studies [13]. 
Harvesting higher parasitaemia cultures in small lysis 
buffer volumes resulted in robust and reproducible trans-
lation activity when the A280 measured in the range of 
7–20 mg/mL. Lysate competency for in vitro translation 
was measured by the translation of the firefly luciferase 
reporter constructs with a P. falciparum 5′ untranslated 
region (UTR) of the ubiquitously expressed erythrocyte 
binding antigen (EBA-175) and a 3′UTR from the P. fal-
ciparum histidine rich protein (Pf HRP) (Fig. 1b). These 
extracts achieved luciferase saturation similar to com-
mercially available rabbit reticulocyte lysate (Retic Lysate 
IVT, Thermo Fisher Scientific), although with slower 
kinetics (Fig. 1c). To verify that the activity of the lysates 
did not result from the negligible amount of ribosome-
containing reticulocytes potentially present in red blood 
cell (RBC) cultures, lysates were isolated from uninfected 
RBC cultures. To attain a comparable concentration of 
material (as measured by A280) from the uninfected RBCs 
(uRBCs) to the P. falciparum lysates, uRBCs were con-
centrated 10-fold using a Centricon YM-10 spin column 
(EMD Millipore, Hayward, CA, USA) and the in  vitro 
translation assay was performed in an identical manner 
with a simultaneously prepared P. falciparum lysate in 
the presence or absence of magnesium (Additional file 1). 
Concentrated uRBCs were unable to produce luciferase 
activity, indicating that the magnesium-dependent trans-
lation activity in this assay is exclusively due to the pres-
ence of P. falciparum ribosomes and not from residual 
human ribosomes present in RBCs. Each batch of P. fal-
ciparum lysate varies in terms of maximum luciferase 
output and time to reach that maximum. Thus, for each 
harvest, a preliminary kinetic assay is necessary to estab-
lish the optimal incubation time (defined as  ~80  % of 
maximum translational activity).
To verify that this assay specifically measures protein 
synthesis, translation activity of the lysate was assessed 
in the presence of 5  μM cycloheximide (27× reported 
IC50 =  181  nM) [14], an inhibitor of general eukaryotic 
translation elongation. When cycloheximide is added 
prior to the 37  °C incubation, translation is inhibited, 
resulting in the absence of luciferase expression, how-
ever, when added following the 37  °C incubation there 
was no effect on translation and the final luciferase 
activity was comparable to a control DMSO sample 
(Fig. 1d). Furthermore, to confirm that the assay is spe-
cific for inhibitors of protein synthesis, and not general 
anti-malarial activity, several anti-malarial compounds at 
1-μM concentration (dihydroartemisinin (DHA), pipe-
raquine, chloroquine, SJ579, and quinine) were tested 
along with 1-μM cycloheximide and found that none 
significantly inhibited translation in the assay with the 
exception of cycloheximide (Fig.  2a). Additionally, in 
both the 1-μM and 5 μM cycloheximide concentrations, 
in every lysate assayed, the measured luciferase activity 
was equivalent to the background (see Fig. 1d and Addi-
tional file 1).
Screening the MMV Malaria Box for translational inhibitors
Screening of the Malaria Box was performed using a 
1-µM drug concentration for 1.5  h at 37  °C using the 
existing layout of the Malaria Box. Each plate was repli-
cated at least three times and normalized to the average 
of all the control wells situated at the peripheral columns 
of each plate, totaling 16 controls wells per plate. A stop 
solution of 5  μM cycloheximide was added immediately 
following the incubation to simultaneously stop all trans-
lation in all wells, providing for uniform temporal meas-
urements of translation throughout the luminescence 
assay. The results of this screen were calculated as a frac-
tional value of the maximum in vitro translation normal-
ized to the average of DMSO controls (Fig. 2b). Standard 
high throughput screen assay parameters were calculated 
(Additional file  2) and resulted in a signal-to-noise ratio 
of >3000, a coefficient of variation of 20.12 % and a Z’ fac-
tor of 0.87. Of all 400 wells assayed, 88.5 % (n = 354) of 
the compounds showed little to no inhibitory effect on 
translation (normalized luciferase ratio >0.80) whereas 46 
compounds showed at least a 20 % inhibition of luciferase 
activity. To be considered further, a conservative cut-off 
was imposed for the standard deviation between repli-
cates to be less than 0.20 of the normalized luciferase ratio 
of each sample. Although the Malaria Box was previously 
screened for cytotoxic effects, a secondary screen was 
performed on the final 15 compounds (standard deviation 
of <0.20 and >20 % normalized luciferase inhibition) using 
commercially available rabbit reticulocyte lysate (also in 
1  μM drug concentration with two replicates) to ensure 
that positive hits did not also block mammalian in  vitro 
translation or inhibit luciferase activity (Retic IVT, Life 
Technologies). A specificity index was defined as the ratio 
of normalized rabbit reticulocyte average translation over 
the normalized P. falciparum average translation. Speci-
ficity ratios ranged from 0.42 to 2.14, with values >1 sig-
nifying compounds that have a greater inhibitory effect on 
P. falciparum translation than rabbit reticulocyte trans-
lation, a proxy for general mammalian translation. After 
filtering for P. falciparum inhibition, standard deviation, 
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rabbit reticulocyte inhibition, and large specificity ratios, 
eight compounds were identified for further analysis 
(Fig.  3). These eight compounds showed a ratio of  >1.2 
and are promising hits for further optimization and lead 
development. The top hit compound, MMV008270, had 
a specificity ratio of 1.96 and inhibited P. falciparum 
in vitro translation by >70 % on average when assayed at 
1uM drug concentration. Next, dose–response curves 
of MMV008270 were characterized to calculate the 
half-maximal inhibitory concentration (IC50) value in 
both the P. falciparum and rabbit reticulocyte systems. 
Dose–response assays were performed in duplicate, with 
a 12-point 1:3 dilution series starting at a high concen-
tration of 250 μM (Fig. 4). The resulting IC50 value for P. 
falciparum was 263 nM whereas the IC50 value for rabbit 
reticulocyte was 494  nM, a 1.89× higher IC50 value and 
consistent with the initial specificity index of 1.96× higher 



























































































Fig. 2 In vitro translation assay drug screens. a Lysates were incubated in the presence of anti-malarials and cycloheximide, a general eukaryotic 
translation inhibitor, all at 1 μM final concentration. Error bars represent the standard deviation among three biological replicates. b MMV Malaria 
Box compounds were added to lysates at a 1 μM final concentration. The average of three biological replicates were used to determine the extent 
of translation inhibition and normalized to the average of the DMSO controls present in each plate. Each point on the graph is the averaged 
response of a single drug. Each point is colour-coded by type of effect: top hit compound, no P. falciparum inhibition, high standard deviation, or 
inhibition in rabbit reticulocyte. The histogram on the right of the graph displays the total percentage of compounds with the given luciferase ratio




























































Fig. 3 Flow diagram and results of the Malaria Box screen. Starting with 400 compounds, each compound was tested in three independent 
biological replicates in in vitro translation assays with 1 μM of the compound. Of the 46 compounds that achieved at least 20 % inhibition of transla-
tion, only eight passed both the standard deviation filter, and specificity filter removing general eukaryotic translation inhibitors (as measured by 
translation inhibition in rabbit reticulocyte lysate) and luciferase inhibitors. a–h Structures of the eight compounds that passed the primary and 
secondary screens. The letter of each structure is matched to the compounds listed in Table 1
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The CHEMBL MMV databases were inspected for bioas-
says results of this compound. A listed Novartis study on 
the cytotoxicity in human fibroblasts calculates an IC50 
for this compound above 32  μM suggesting low in  vivo 
activity or penetrance in mammalian cells (Table 1) [15]. 
Additionally, an analogue (MMV006937) of the hit com-
pound included in the Malaria Box set differs by the pres-
ence of a single hydrogen bond on the benzene ring and 
did not inhibit translation in the in vitro assay (% normal-
ized luciferase translation MMV006937 = 83 %), suggest-
ing a high degree of structural specificity associated with 
the inhibitory activity of the original hit. Further structure 
activity relationship studies of this compound will focus 
on the development of more specific and potent inhibi-
tors of P. falciparum translation relative to a mammalian 
counterpart.
Discussion
This work presents a novel high-throughput luciferase 
assay that enables the discovery of compounds inhibiting 
eukaryotic protein synthesis in P. falciparum. This cell-
free system is sensitive to the known translation inhibi-
tor cycloheximide, whereas anti-malarials with no known 
effect on translation, such as chloroquine and DHA, do 
not exhibit inhibitory activity in the assay. Utilizing this 
novel assay resulted in the identification of eight com-
pounds that are inhibitors of P. falciparum translation, 
and more effectively inhibit P. falciparum than mam-
malian in  vitro translation. Considering that this assay 
is based on a crude extract that naturally has more vari-
ability than a pure enzyme assay, additional secondary 
screening (such as IC curves in this case) is required 
to establish their validity. Of these eight compounds, 
further characterization of the top hit, MMV008270, 
showed 1.9× higher activity against P. falciparum trans-
lation over a general eukaryotic translation system. While 
a 1.9× difference is likely to be too narrow for serious 
consideration as a lead molecule, it provides a starting 
point for further structure activity relationship studies 
with the goal of widening the gap between P. falciparum 
and mammalian inhibition. Further, target validation by 
selection for resistance may aid in determining which 
component of the ribosomal machinery is the target of 
this compound. It is likely that multiple components of 
the ribosome could be targeted simultaneously to yield a 
synergistic effect.


























Fig. 4 Dose–response curves of MMV008270. Dose-response curves 
in P. falciparum lysate or rabbit reticulocyte lysate using a 12-point 1:3 
titration starting at 250 μM. Data were normalized to background and 
DMSO-only controls. IC50 values for each system are listed below the 
graph
Table 1 Eight top hit compounds
After filtering for several attributes, this study offers a final list of eight hit compounds. The chemical structure letter corresponds to the structures found in Fig. 3. 
Listed in this Table are the CHEMBL names, MMV number, any alternative compound name found in databases, the average normalized luciferase output, specificity 
















a CHEMBL600904 MMV008270 GNF-Pf-780 0.27 1.96 1.93 >32000 nM
b CHEMBL536393 MMV019124 TCMDC-123658 0.39 2.05 0.51 >32000 nM
c CHEMBL532525 MMV665886 TCMDC-125438 0.62 1.69 0.77 >32000 nM
d CHEMBL589060 MMV666057 TCMDC-125853 0.71 1.55 0.61 >32000 nM
e CHEMBL546994 MMV666693 TCMDC-124577 0.71 1.57 0.06 >32000 nM
f CHEMBL588732 MMV007564 GNF-Pf-
4877;TCMDC-124400
0.72 1.51 0.53; 0.75 >32000 nM
g CHEMBL1198651 MMV007764 GNF-Pf-4338 0.74 1.59 0.31 =19329.43 nM
h CHEMBL530149 MMV006767 GNF-Pf-
3828;TCMDC-123992
0.75 1.61 0.41; 1.13 >32000 nM
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The assay developed here has the potential to be a pow-
erful tool for additional translation-specific drug screens 
as well as answering important questions of basic Plas-
modium biology. For example, future experiments using 
this streamlined, multi-well, plate-friendly assay will 
allow for the further investigation of cis-acting determi-
nants of translational efficiency that were identified in a 
previous study [16]. In total, this work presents a valuable 
molecular tool for probing an essential process in P. falci-
parum biology.
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